<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200925048838N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-10-12</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of  borage tea on sleep disorders in postmenopausal women</public_title>
      <acronym></acronym>
      <scientific_title>The effect of  borage tea on sleep disorders in postmenopausal women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-11-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51393</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is performed using a random number table to create quadruple blocks in a one-to-one ratio that will be placed in two groups of 30 people to intervene and control, Blinding description: In this study, according to the apparent simulation in prescription tea and the use of a cup of the same size for similarity of the concentration of the substance in the two groups, the researcher and the participants do not know each person is in which group.</study_design>
      <phase>3</phase>
      <hc_freetext>sleep disorders in postmenopausal women..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: For this patient, if they have the inclusion criteria, after providing explanations about the dissertation plan and obtaining informed consent; before the intervention, the demographic information form, PSQL questionnaire and ISI questionnaire will be completed. 2-grams of borage tea is applied every night before going to bed for 8 weeks. a cup of the same size is purchased and given to all intervention groups to determine the same concentration. 8 weeks after the intervention, the questionnaires will be completed again by all subjects. Intervention 2: Control group: For this patient, if they have the inclusion criteria, after providing explanations about the dissertation plan and obtaining informed consent; before the intervention, the demographic information form, PSQL questionnaire and ISI questionnaire will be completed. In the control group, the intervention is applied by placebo. The placebo will also contain wheat germ powder in a 2-grams bag, which is quite similar in appearance to the bag containing 2-grams of borage tea and is given every night before bed for 8 weeks. Also, for all members of the group, a cup of the same size is purchased and given to determine the uniform concentration of the placebo. 8 weeks after the intervention, the questionnaires will be completed again by all subjects. It should be noted that the ineffectiveness of wheat germ on sleep disorders has been proven.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Leila Ghasemzadehdehkorde</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Padadshahr 18th West Street</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6395137149</zip>
        <telephone>+98 61 4372 2717</telephone>
        <email>ghasemzadeh.L@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mitra Tadayon Najafabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golestan Blvd., Esfand Ave</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>15794- 61357</zip>
        <telephone>+98 61 3336 7543</telephone>
        <email>tadayon-m@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Amenorrhea for at least 12 years.
60-45 years old.
Score more than 5 on the Pittsburgh Questionnaire</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Occurrence of any physical or psychological disorder during the study that causes sleep disorders.
Discontinuation of borage tea consumption by the subject for any reason before the end of the intervention period
Having an underlying disease ( hypertension - diabetes)
Use of hormone therapy.
Having Chronic disease (heart, kidney, diabetes, hypertension)
Consumption of alcohol and addictive substances.
Having an allergy to borage
Taking benzodiazepines pills during the last 3 months.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G47</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Sleep disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: For this patient, if they have the inclusion criteria, after providing explanations about the dissertation plan and obtaining informed consent; before the intervention, the demographic information form, PSQL questionnaire and ISI questionnaire will be completed. 2-grams of borage tea is applied every night before going to bed for 8 weeks. a cup of the same size is purchased and given to all intervention groups to determine the same concentration. 8 weeks after the intervention, the questionnaires will be completed again by all subjects.</i_keyword>
      <i_keyword>Control group: For this patient, if they have the inclusion criteria, after providing explanations about the dissertation plan and obtaining informed consent; before the intervention, the demographic information form, PSQL questionnaire and ISI questionnaire will be completed. In the control group, the intervention is applied by placebo. The placebo will also contain wheat germ powder in a 2-grams bag, which is quite similar in appearance to the bag containing 2-grams of borage tea and is given every night before bed for 8 weeks. Also, for all members of the group, a cup of the same size is purchased and given to determine the uniform concentration of the placebo. 8 weeks after the intervention, the questionnaires will be completed again by all subjects. It should be noted that the ineffectiveness of wheat germ on sleep disorders has been proven.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sleep disorder in postmenopausal women. Timepoint: Pre-intervention, 8 weeks after the start of the intervention. Method of measurement: Variables are measured by demographic questionnaire, Pittsburg Sleep Quality Index (PSQL) and Insomnia Severity Index (ISI).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Sleep disorders in postmenopausal women. Timepoint: Pre-intervention, 8 weeks after the start of the intervention. Method of measurement: Variables are measured by demographic questionnaire, Pittsburg Sleep Quality Index (PSQL) and Insomnia Severity Index (ISI).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-12-09</approval_date>
        <contact_name>Ethics committee of Ahvaz University of Medical Sciences</contact_name>
        <contact_address>Esfand Ave., Golestan Blvd., Ahvaz Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
